Bind Appoints CSO
This article was originally published in Scrip
Bind Therapeutics, Inc. has appointed Jonathan Yingling chief scientific officer (CSO). Before joining Bind, Yingling was vice president of oncology discovery and translation research at Bristol-Myers Squibb. His pharmaceutical career began in 2000 as a senior biologist in oncology at Eli Lilly & Co., where he spent 13 years in various positions including CSO of angiogenesis and tumor microenvironment biology, vice president of oncology research and vice president of translation science and technology.